Compare Nu Holdings Ltd (NU) vs TG Therapeutics Inc (TGTX) Price & Performance

NU stock trades at $13.615, down 1.77% on the day, amid bearish technical signals but strong fundamentals. Revenue grew from $3.0B in 2022 to $10.63B in 2025, with net income turning positive to $2.87B. The company recently announced a Brazilian banking license acquisition (PYMNTS, 2026-07-22), supporting expansion. Analysts maintain a buy consensus with a $14.98 target, though recent earnings misses and competitive pressures pose headwinds.

Outlook: NU's robust growth trajectory and high ROE (30.04% as of 2025) offer upside, but technical weakness and Latin American market risks require caution. The Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) is a key catalyst, with expectations of $0.1984 EPS. Investors should weigh strong profitability against bearish momentum and rising competition.

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.